The Hereditary Angioedema (Hae) Therapeutics Market is segmented by End-user (Hospital pharmacies, Retail pharmacies, and E-commerce), Product (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW)). As per the Global Forecast research report 2024-2028 published by Technavio, the market size is estimated to grow by USD 2192.1 million, at a CAGR of 10.59% during the forecast period. There are several companies that are contributing to the market as per this report. Growing demand for personalized medicine .
The Hereditary Angioedema (HAE) therapeutics market represents a significant business opportunity due to the rising prevalence of this debilitating condition. HAE is characterized by recurrent episodes of swelling, primarily in the face, hands, feet, genitals, and gastrointestinal tract. Current treatments focus on preventing or reducing the frequency and severity of attacks through various modalities, including plasma derivatives, small molecule inhibitors, and gene therapy. The market is expected to grow substantially due to the unmet medical need, increasing awareness, and the launch of novel therapeutics. Companies are investing heavily in research and development to bring innovative solutions to market and capture a share of this lucrative sector.
For insights on company offerings- Request a sample report!
The Hereditary Angioedema (HAe) therapeutics market represents a significant business opportunity due to the increasing prevalence of this rare and debilitating condition. Key players in this market are developing innovative treatments to address the unmet medical needs of HAe patients. These include novel therapies such as plasma-derived C1 inhibitor, recombinant C1 inhibitor, and gene therapy. Market growth is driven by the rising incidence of HAe, increasing awareness, and favorable regulatory environments. Strategic collaborations and partnerships are also shaping the competitive landscape.
To access the valuable insights - Download the Free Sample Report
Hereditary Angioedema (HAE) is a rare and debilitating genetic disorder characterized by recurrent episodes of edema (swelling) in various parts of the body, including the face, airways, feet, hands, and blood vessels. The condition is caused by a dysfunctional C1 inhibitor protein due to a spontaneous mutation in the C1 inhibitor gene. HAE is classified into three types: Type I, Type II, and Type III. The HAE therapeutics market includes various drugs, with Kallikrein inhibitors being a prominent drug class. These inhibitors prevent the activation of Kallikrein, which plays a role in the development of HAE symptoms. Oral prophylaxis using Kallikrein inhibitors, such as Donidalorsen, is becoming increasingly popular due to its convenience and effectiveness. Clinical allergists, gastroenterologists, dermatologists, and other physicians play a crucial role in diagnosing and managing HAE. Retail pharmacies are also essential in ensuring patients have access to these life-saving medications. With an estimated prevalence of 1 in 50,000 to 1 in 100,000, the demand for effective HAE therapies continues to grow. HAE is an immune system disorder that affects the synthesis of C1 inhibitor, leading to the accumulation of bradykinin, which causes edema. Understanding the underlying causes of HAE and the availability of effective therapeutics, such as Kallikrein inhibitors, is crucial in improving the quality of life for those affected by this condition.
The global pharmaceuticals market encompasses businesses involved in the research and development (R&D) or production of various categories of drugs, including generic and non-generic medicines, as well as veterinary drugs. According to Technavio's market analysis, the healthcare industry's size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the expansion of the pharmaceuticals sector include the increasing aging population. By 2050, approximately one-quarter of the US population and by 2030 in Europe are anticipated to be over 60 years old, leading to a significant rise in demand for healthcare solutions, including Hereditary Angioedema (HAE) therapeutics. - The Hereditary Angioedema (Hae) Therapeutics Market is experiencing significant growth, fueled by the . Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
